These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9041479)

  • 41. Hereditary haemochromatosis - diagnosis and management.
    Allen K
    Aust Fam Physician; 2010 Dec; 39(12):938-41. PubMed ID: 21301675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diurnal variations of the serum iron in normal subjects and in patients with haemochromatosis.
    Sinniah R; Doggart JR; Neill DW
    Br J Haematol; 1969 Oct; 17(4):351-8. PubMed ID: 5346408
    [No Abstract]   [Full Text] [Related]  

  • 43. Should we genetically test everyone for haemochromatosis?
    Allen K; Williamson R
    J Med Ethics; 1999 Apr; 25(2):209-14. PubMed ID: 10226930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-transferrin plasma iron.
    Hershko C; Peto TE
    Br J Haematol; 1987 Jun; 66(2):149-51. PubMed ID: 3606953
    [No Abstract]   [Full Text] [Related]  

  • 45. Haemochromatosis screening.
    Tanner AR; Wright R
    Lancet; 1988 Jul; 2(8605):286. PubMed ID: 2899281
    [No Abstract]   [Full Text] [Related]  

  • 46. The binding and transport of iron by transferrin variants.
    TURNBULL A; GIBLETT ER
    J Lab Clin Med; 1961 Mar; 57():450-9. PubMed ID: 13778706
    [No Abstract]   [Full Text] [Related]  

  • 47. Screening for hemochromatosis: additional considerations.
    Phatak PD; Sham RL; Cappuccio JD
    Gastroenterology; 1996 Feb; 110(2):653-4. PubMed ID: 8566621
    [No Abstract]   [Full Text] [Related]  

  • 48. The Role of Iron in Type 1 Diabetes Etiology: A Systematic Review of New Evidence on a Long-Standing Mystery.
    Søgaard KL; Ellervik C; Svensson J; Thorsen SU
    Rev Diabet Stud; 2017; 14(2-3):269-278. PubMed ID: 29145537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population screening for haemochromatosis: a unifying analysis of published intervention trials.
    Bradley LA; Haddow JE; Palomaki GE
    J Med Screen; 1996; 3(4):178-84. PubMed ID: 9041481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands.
    Bradley LA; Haddow JE; Palomaki GE
    J Med Screen; 1996; 3(4):171-7. PubMed ID: 9041480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of cancer by transferrin saturation levels and haemochromatosis genotype: population-based study and meta-analysis.
    Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Intern Med; 2012 Jan; 271(1):51-63. PubMed ID: 21605201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HLA determinants in idiopathic haemochromatosis.
    Milman N; Graudal N; Nielsen LS; Sørensen SA
    Dan Med Bull; 1985 Oct; 32(5):262-4. PubMed ID: 4053696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening for haemochromatosis.
    Edwards CQ
    J Med Screen; 1996; 3(4):170. PubMed ID: 9041479
    [No Abstract]   [Full Text] [Related]  

  • 54. Screening for hemochromatosis: phenotype versus genotype.
    Edwards CQ; Griffen LM; Ajioka RS; Kushner JP
    Semin Hematol; 1998 Jan; 35(1):72-6. PubMed ID: 9460810
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.